PD-L1
Concentrated and Prediluted Rabbit Monoclonal Antibody
901-3171-053023

Available Product Formats

<table>
<thead>
<tr>
<th>Format</th>
<th>Catalog Number</th>
<th>Description</th>
<th>Dilution</th>
<th>Diluent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Concentrate</td>
<td>ACI 3171 A, C</td>
<td>0.1, 1.0 mL</td>
<td>1:100</td>
<td>Renoir Red</td>
</tr>
<tr>
<td>Predilute</td>
<td>API 3171 AA</td>
<td>6.0 mL</td>
<td>Ready-to-use</td>
<td>N/A</td>
</tr>
<tr>
<td>ONCORE Pro</td>
<td>OPAI 3171 T60</td>
<td>60 tests</td>
<td>Ready-to-use</td>
<td>N/A</td>
</tr>
<tr>
<td>VALENT</td>
<td>VLTR 3171 G20</td>
<td>20 mL</td>
<td>Ready-to-use</td>
<td>N/A</td>
</tr>
<tr>
<td>UltraLine – For Benchmark</td>
<td>AVI 3171 G</td>
<td>6.0 mL</td>
<td>Ready-to-use</td>
<td>N/A</td>
</tr>
</tbody>
</table>

**Intended Use:**
For In Vitro Diagnostic Use
PD-L1 [CAL10] is a rabbit monoclonal antibody that is intended for laboratory use in the qualitative identification of PD-L1 protein by immunohistochemistry (IHC) in formalin-fixed paraffin-embedded (FFPE) human tissues. The clinical interpretation of any staining or its absence should be complemented by morphological studies using proper controls and should be evaluated within the context of the patient's clinical history and other diagnostic tests by a qualified pathologist.

**Summary and Explanation:**
Programmed death ligand 1 (PD-L1, also known as CD274) inhibits tumor-reactive T cells via binding to the programmed death-1 (PD-1) receptor, rendering tumor cells resistant to PD-1-mediated lysis (1). Studies have shown that the inhibitory receptor PD-1 is expressed on tumor-infiltrating lymphocytes (TIL) while PD-L1 is expressed on tumor cells. Assessment of PD-L1 expression in combination with CD8+ TIL density may be a useful predictive metric in multiple cancers, including stage III NSCLC, hormone receptor negative breast cancer and sentinel lymph node melanoma (2-4). Clinical trials utilizing humanized chimeric antibodies that block inhibitory checkpoints, such as anti-PD-1 and anti-PD-L1, have demonstrated delayed tumor growth and increased survival (5). While identification of PD-L1, also known as CD274) inhibits tumor-reactive T cells via binding to the programmed death-1 (PD-1) receptor is not yet standardized, it has become increasingly important to identify these tumors, as a directed therapy may improve clinical outcomes in these patients (6). In cutaneous melanoma, the targeting of PD-1/PD-L1 has provided meaningful clinical benefit for patients in just the past 5-10 years (7). The use of IHC for protein identification, along with novel therapies, such as checkpoint inhibitors and vaccines, are generating new options for the treatment of cancer patients. The PD-L1 [CAL10] clone does not cross react with PD-L2.

**Principle of Procedure:**
Antigen detection in tissues and cells is a multi-step immunohistochemical process. The initial step binds the primary antibody to its specific epitope. After labeling the antigen with a primary antibody, a one-step or two-step detection procedure can be applied. A one-step procedure will feature an enzyme labeled polymer that binds the primary antibody. A two-step procedure will feature a linker antibody added to bind to the primary antibody. An enzyme-labeled polymer is then added to bind the linker antibody. These detections of the bound antibodies are evidenced by a colorimetric reaction.

**Source:** Rabbit monoclonal

**Species Reactivity:** Human; others not tested

**Clone:** CAL10

**Isotype:** IgG

**Protein Concentration:** Call for lot specific Ig concentration.

**Epitope/Antigen:** Peptide corresponding to the region within human PD-L1

**Cellular Localization:** Membranous/cytoplasmic

**Positive Tissue Control:** Lung adenocarcinoma or tonsil

**Known Applications:**
Immunohistochemistry (formalin-fixed paraffin-embedded tissues)

**Supplied As:** Buffer with protein carrier and preservative

**Storage and Stability:**
Store at 2°C to 8°C. The product is stable to the expiration date printed on the label, when stored under these conditions. Do not use after expiration date. Diluted reagents should be used promptly; any remaining reagent should be stored at 2°C to 8°C.

**Protocol Recommendations (VALENT® Automated Slide Staining Platform):**
VLTR3171 is intended for use with the VALENT. Refer to the User Manual for specific instructions for use. Protocol parameters in the Protocol Manager should be programmed as follows:

**Deparaffinization:** Deparaffinize for 8 minutes with Val DePar.

**Pretreatment:** Perform heat retrieval at 98°C for 60 minutes using Val AR-Hi pH, 5X (use at 1X).

**Peroxidase Block:** Block for 5 minutes with Val Peroxidase Block.

**Protein Block:** Incubate for 10 minutes with Val Background Block.

**Primary Antibody:** Incubate for 45 minutes.

**Secondary:** N/A

**Linker:** Incubate for 10 minutes with Val Universal Linker.

**Polymer:** Incubate for 20 minutes with Val Universal Polymer.

**Chromogen:** Incubate for 5 minutes with Val DAB.

**Counterstain:** Counterstain for 5 minutes with Val Hematoxylin.

**Protocol Recommendations (intelliPATH FLX® and manual use):**

**Peroxide Block:** Block for 5 minutes with Peroxidized 1.

**Pretreatment:** Perform heat retrieval using Diva Decloaker. Refer to the Diva Decloaker data sheet for specific instructions.

**Protein Block (Optional):** Incubate for 5-10 minutes at RT with Background Punisher.

**Primary Antibody:** Incubate for 30 minutes at RT.

**Probe:** N/A

**Polymer:** Incubate for 30 minutes at RT with a secondary-conjugated polymer.

**Chromogen:** Incubate for 5 minutes at RT with Biocare’s DAB – OR – Incubate for 5-7 minutes at RT with Warp Red.

**Counterstain:** Counterstain with hematoxylin. Rinse with deionized water. Apply Tacha’s Bluing Solution for 1 minute. Rinse with deionized water.

**Technical Note:**
1. This antibody, for intelliPATH FLX and manual use, has been standardized with Mach 4 detection system. Use TBS for washing steps.
2. This clone demonstrates a weak protein expression in endothelial cells.
Protocol Recommendations (ONCORE™ Pro Automated Slide Staining System):

OPAI3171 is intended for use with the ONCORE Pro. Refer to the User Manual for specific instructions for use. Protocol parameters in the Protocol Editor should be programmed as follows:

**Protocol Name**: PD-L1 Rb

**Protocol Template (Description)**: Rabbit HRP Template 1

**Dewaxing (DS Buffer Option)**: DS2-50

**Antigen Retrieval (AR Option)**: AR2, low pH; 101°C

**Block Option**: Buffer

**Reagent Name, Time, Temp.**: PD-L1 Rb, 30 min., 25°C

Protocol Recommendations (Ventana BenchMark ULTRA):

AVI3171 is intended for use with the BenchMark ULTRA. Refer to the User Manual for specific instructions for use. Recommended protocol parameters are as follows:

**Template/Detection**: OptiView DAB IHC

**Pretreatment Protocol**: CC1 64 minutes

** Peroxidase**: Pre Primary Peroxidase Inhibitor

**Primary Antibody**: 60 minutes, 36°C

**Limitations**: The optimum antibody dilution and protocols for a specific application can vary. These include, but are not limited to fixed, heat-retrieval method, incubation times, tissue section thickness and detection kit used. Due to the superior sensitivity of these unique reagents, the recommended incubation times and titers listed are not applicable to other detection systems, as results may vary. The data sheet recommendations and protocols are based on exclusive use of Biocare products. Ultimately, it is the responsibility of the investigator to determine optimal conditions.

**Quality Control**: Refer to CLSI Quality Standards for Design and Implementation of Immunohistochemistry Assays; Approved Guideline-Second edition (I/LA28-A2) CLSI Wayne, PA USA (www.clsi.org). 2011

**Precautions**: 1. This antibody contains less than 0.1% sodium azide. Concentrations less than 0.1% are not reportable hazardous materials according to U.S. 29 CFR 1910.1200, OSHA Hazard communication and EC Directive 91/155/EC. Sodium azide (NaN₃) used as a preservative is toxic if ingested. Sodium azide may react with lead and copper plumbing to form highly explosive metal azides. Upon disposal, flush with large volumes of water to prevent azide build-up in plumbing. (Center for Disease Control, 1976, National Institute of Occupational Safety and Health, 1976) (8)

2. Specimens, before and after fixation, and all materials exposed to them should be handled as if capable of transmitting infection and disposed of with proper precautions. Never pipette reagents by mouth and avoid contacting the skin and mucous membranes with reagents and specimens. If reagents or specimens come into contact with sensitive areas, wash with copious amounts of water. (9)

3. Microbial contamination of reagents may result in an increase in nonspecific staining.

4. Incubation times or temperatures other than those specified may give erroneous results. The user must validate any such change.

5. Do not use reagent after the expiration date printed on the vial.

6. The SDS is available upon request and is located at http://biocare.net.

**Troubleshooting**: Follow the antibody specific protocol recommendations according to the data sheet provided. If atypical results occur, contact Biocare's Technical Support at 1-800-542-2002.

**References**:


VP Echelon Series antibodies are developed solely by Biocare Medical LLC and do not imply approval or endorsement of Biocare’s antibodies by Ventana Medical Systems, Inc. Biocare and Ventana are not affiliated, associated or related in any way. Ventana®, BenchMark®, ultraView and OptiView are trademarks of Roche.